Assure (IONM) 10-Q 14 May 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2021
Entity File Number	333-251829
Entity Registrant Name	ASSURE HOLDINGS CORP.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	82-2726719
Entity Address, Address Line One	4600 South Ulster Street, Suite 1225
Entity Address, City or Town	Denver
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80237
City Area Code	720
Local Phone Number	287-3093
Title of 12(b) Security	Common Stock, $0.001 Par Value
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		56,606,634
Entity Central Index Key	0001798270
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets
Cash	$ 4,080	$ 4,386
Accounts receivable, net	15,710	14,965
Income tax receivable	150	150
Other current assets	807	618
Due from PEs	5,031	4,856
Total current assets	25,778	24,975
Equity method investments	416	608
Property, plant and equipment, net	305	356
Operating lease right of use asset	67	124
Finance lease right of use asset	764	608
Intangibles, net	3,998	4,115
Goodwill	2,857	2,857
Total assets	34,185	33,643
Current liabilities
Accounts payable and accrued liabilities	2,934	2,871
Current portion of debt	4,100	4,100
Current portion of lease liability	623	521
Other current liabilities	72	96
Total current liabilities	7,729	7,588
Lease liability, net of current portion	789	772
Debt, net of current portion	4,011	2,251
Acquisition share issuance liability	540	540
Fair value of stock option liability	19	16
Performance share issuance liability	2,081	2,668
Deferred tax liability, net	172	599
Total liabilities	15,341	14,434
Commitments and contingencies (Note 7)
SHAREHOLDERS' EQUITY
Common stock: $0.001 par value; 900,000,000 shares authorized; 56,598,777 and 56,378,939 shares issued and outstanding, as of March 31, 2021 and December 31, 2020, respectively	56	56
Additional paid-in capital	31,707	30,841
Accumulated deficit	(12,919)	(11,688)
Total shareholders' equity	18,844	19,209
Total liabilities and shareholders' equity	$ 34,185	$ 33,643

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
CONDENSED CONSOLIDATED BALANCE SHEETS
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	900,000,000	900,000,000
Common stock, shares issued	56,598,777	56,378,939
Common stock, shares outstanding	56,598,777	56,378,939

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue
Total revenue	$ 4,765	$ 4,333
Cost of revenues	2,532	1,798
Gross margin	2,233	2,535
Operating expenses
General and administrative	3,132	2,246
Sales and marketing	335	221
Depreciation and amortization	285	259
Total operating expenses	3,752	2,726
Loss from operations	(1,519)	(191)
Other income/(expenses)
Loss from equity method investments	(23)	(107)
Other income (expense), net	(3)	57
Accretion expense	(95)	(185)
Interest expense, net	(18)	(53)
Total other expense	(139)	(288)
Loss before income taxes	(1,658)	(479)
Income tax benefit	427	65
Net loss	$ (1,231)	$ (414)
Loss per common share
Basic	$ (0.02)	$ (0.01)
Diluted	$ (0.02)	$ (0.01)
Weighted average number of common shares used in per share calculation - basic	56,537,711	34,795,313
Weighted average number of common shares used in per share calculation - diluted	56,537,711	34,795,313
Patient service fees, net
Revenue
Total revenue	$ 2,950	$ 2,346
Hospital, management and other
Revenue
Total revenue	$ 1,815	$ 1,987

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities
Net loss	$ (1,231)	$ (414)
Adjustments to reconcile net loss to net cash used in operating activities
Cash receipts from operations	3,067	2,960
Losses from equity method investments	23	107
Stock-based compensation	279	205
Depreciation and amortization	285	259
Provision for stock option fair value	3	(57)
Accretion expense	95	185
Tax impact of equity component of convertible debt issuance		(173)
Change in operating assets and liabilities
Accounts receivable, net	(3,812)	(2,751)
Prepaid expenses	(151)
Right of use assets	(216)	22
Accounts payable and accrued liabilities	62	156
Due from related parties	(213)	(1,072)
Lease liability	120	(128)
Income taxes	(427)	110
Other assets and liabilities	(24)	18
Net cash used in operating activities	(2,140)	(573)
Cash flows from investing activities
Purchase of equipment and furniture		(35)
Acquisition debt		(530)
Distributions received from equity method investments	169	185
Net cash provided by (used in) investing activities	169	(380)
Cash flows from financing activities
Repayment of promissory note		(130)
Proceeds from Payroll Protection Program loan	1,665
Proceeds from convertible debenture		1,605
Net cash provided by financing activities	1,665	1,475
Increase (decrease) in cash	(306)	522
Cash at beginning of period	4,386	59
Cash at end of period	4,080	581
Supplemental cash flow information
Interest paid	196	51
Supplemental non-cash flow information
Purchase of equipment with finance leases	$ 273	$ 90

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional paid-in capital	Retained Earnings	Total
Balance at beginning of period at Dec. 31, 2019	$ 35	$ 6,682	$ 3,348	$ 10,065
Balance at beginning of period (in shares) at Dec. 31, 2019	34,795,313
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		205		205
Expected tax loss of future stock compensation option exercises		(173)		(173)
Equity component of convertible debt issuance		754		754
Fair value of finders' warrants		32		32
Net loss			(414)	(414)
Balance at end of period at Mar. 31, 2020	$ 35	7,500	2,934	10,469
Balance at end of period (in shares) at Mar. 31, 2020	34,795,313
Balance at beginning of period at Dec. 31, 2020	$ 56	30,841	(11,688)	19,209
Balance at beginning of period (in shares) at Dec. 31, 2020	56,378,939
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation		279		279
Settlement of performance share liability		587		587
Settlement of performance share liability (in shares)	219,838
Net loss			(1,231)	(1,231)
Balance at end of period at Mar. 31, 2021	$ 56	$ 31,707	$ (12,919)	$ 18,844
Balance at end of period (in shares) at Mar. 31, 2021	56,598,777

NATURE OF OPERATIONS

NATURE OF OPERATIONS	3 Months Ended
	Mar. 31, 2021
NATURE OF OPERATIONS
NATURE OF OPERATIONS	1. ​ Assure Holdings Corp. (the “Company” or “Assure”), through its two indirect wholly-owned subsidiaries, Assure Neuromonitoring, LLC (“Neuromonitoring”) and Assure Networks, LLC (“Networks”), provides technical and professional intraoperative neuromonitoring (“IONM”) surgical support services primarily associated with spine and head surgeries. These services have been recognized as the standard of care by hospitals and surgeons for risk mitigation. Assure Holdings, Inc., a wholly-owned subsidiary, employs most of the corporate employees and performs various corporate services on behalf of the consolidated Company. Neuromonitoring employs technologists who utilize technical equipment and their technical training to monitor EEG ( electroencephalogram) electromyography) Networks performs similar support services as Neuromonitoring except that these services are provided by third party contracted neurologists or certified readers. The support services provided by Networks occurs at the same time and for the same surgeries as the support services provided by the Neuromonitoring technologist, except that they typically occur at an offsite location. The Company was originally incorporated in Colorado on November 7, 2016. In conjunction with a reverse merger, the Company was redomiciled in Nevada on May 16, 2017. Neuromonitoring was formed on August 25, 2015 in Colorado and it currently has multiple wholly-owned subsidiaries. The Company’s services are sold in the United States, directly through the Company. Networks was formed on November 7, 2016 in Colorado and holds varying ownerships interests in numerous Provider Network Entities (“PEs”), which are professional IONM entities. These entities are accounted for under the equity method of accounting. Additionally, Networks manages other PEs that Networks does not have an ownership interest and charges those PEs a management fee. The Company operates in one segment. COVID-19 In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19 coronavirus has spread to over 150 countries and every state in the United States. On January 30, 2020, the World Health Organization declared the outbreak of coronavirus a “Public Health Emergency of International Concern.” On March 11, 2020, the World Health Organization declared the outbreak a pandemic, and on March 13, 2020, the United States declared a national emergency. The spread of the virus in many countries continues to adversely impact global economic activity and has contributed to significant volatility and negative pressure in financial markets and supply chains. The pandemic has had, and could have a significantly greater, material adverse effect on the U.S. economy where we conduct our business. The pandemic has resulted, and may continue to result for an extended period, in significant disruption of global financial markets, which may reduce our ability to access capital in the future, which could negatively affect our liquidity. Operations related to the support of surgical procedures may experience a delay in implementation due to the pandemic, including delays and cancellations of elective procedures. The COVID-19 pandemic may also impact our workforce, supply chains or distribution networks or otherwise impact our ability to restock our medical device and supply inventories and depending upon the severity of the COVID-19 coronavirus’ continued spread in the United States and other countries, we may experience disruptions that could severely impact our business, including: ● limitation of company operations, including work from home policies and office closures; ● one or more key officers and/or employees could be personally affected by the virus; ● delays or difficulties in scheduling of surgical procedures that use our services; ● delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site staff; ● diversion of healthcare resources away from the elective surgeries, including the diversion of hospitals facilities and hospital staff; ● interruptions due to limitations on travel imposed or recommended by federal or state governments, employers and others; ● limitations in employee resources that would otherwise be focused on our business, due to sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and ● could impact the timing of reimbursement from commercial insurance companies. The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. In early December 2020, authorities in the United Kingdom reported mutations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which may indicate that the virus is replacing older versions of the virus and may increase the ability to infect cells. Subsequently, other mutations have been reported. Since December 11, 2020, the U.S. Food and Drug Administration (“FDA”) issued emergency use authorization (“EUA”) for vaccines developed by Pfizer-BioNTech, Moderna, Inc. and Johnson and Johnson for the prevention of COVID-19 caused SARS-CoV-2. As of May 11, 2021, the Center for Disease Control and Prevention has reported 263 million doses of COVID-19 vaccines have been administered in the United States with 153.4 million people receiving at lease one dose and 116.5 million fully vaccinated. Other vaccine manufacturers are anticipated to receive FDA approval for additional vaccines. The emergency use authorizations allow the vaccines to be distributed in the U.S. While clinical trials of the vaccines demonstrated a high degree of effectiveness, there remains uncertainty as to the effectiveness of the vaccines outside clinical trials, the timing of the rollout of the vaccines, the immunization and acceptance rate, potential side effects of the vaccines, potential mutation of COVID-19 in response to the vaccines and other risks and uncertainties. The extent to which the COVID-19 coronavirus may continue to impact our business and our profitability and growth will depend on future developments to combat COVID-19, which are highly uncertain and cannot be predicted with confidence, such as the effectiveness of vaccines, the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease. Health & Safety Measures Assure has taken include: ● cancellation of all non-essential travel; ● indefinite work from home policy for all employees not engaged in on-site medical facility activities; ● mandatory self-quarantine for anyone who has experienced any flu-like symptoms or has had contact with anyone believed to have been exposed to COVID-19; and ● capital and financial measures to increase cash position and preserve financial flexibility. ​ Significant uncertainty remains as to the potential impact of the COVID-19 pandemic on our operations, and on the global economy as a whole.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2021
BASIS OF PRESENTATION
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, and majority-owned entities. The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), which contemplates continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying consolidated financial statements do not include any adjustments that might become necessary should the Company be unable to continue as a going concern. All significant intercompany balances and transactions have been eliminated in consolidation. For entities in which management has determined the Company does not have a controlling financial interest but has varying degrees of influence regarding operating policies of that entity, the Company’s investment is accounted for using the equity method of accounting. There have been no changes to the Company’s accounting policies or recent accounting pronouncement as disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 as filed on March 30, 2021.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2021
LEASES
LEASES	3. LEASES Under ASC 842, Leases Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet; the Company recognizes lease expense for these leases on a straight-line basis over the lease term. As a practical expedient, the Company elected not to separate nonlease components for the corporate office facility (e.g., common-area maintenance costs) from lease components (e.g., fixed payments including rent) and instead to account for each separate lease component and its associated non-lease components as a single lease component. Operating leases The Company leases corporate office facilities under two operating sub-leases which expire June 30, 2021. Finance leases The Company leases medical equipment under financing leases with stated interest rates ranging from 6.5% — 12.2% per annum which expire at various dates through 2026. The consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of March 31, 2021 and December 31, 2020 (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2021 2020 Operating $ 67 $ 124 Finance ​ 764 ​ 608 Total $ 831 $ 732 ​ Finance lease assets are reported net of accumulated amortization of $1.4 million and $1.3 million as of March 31, 2021 and December 31, 2020, respectively. ​ The following are the components of lease cost for operating and finance leases (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2021 2020 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases ​ $ 64 ​ $ 44 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 117 ​ ​ 111 Interest on lease liabilities ​ ​ 17 ​ ​ 18 Total finance lease cost ​ ​ 134 ​ ​ 129 Total lease cost ​ $ 198 ​ $ 173 ​ ​ The following are the weighted average lease terms and discount rates for operating and finance leases: ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2021 ​ Weighted average remaining lease term: ​ ​ ​ Operating leases 0.3 years Finance leases 3.5 years Weighted average discount rate: ​ ​ ​ Operating leases 6.9 % Finance leases 8.0 % ​ The Company acquired ROU assets in exchange for lease liabilities of $273 thousand upon commencement of finance leases during the three months ended March 31, 2021. Future minimum lease payments and related lease liabilities as of March 31, 2021 were as follows (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder 2021 ​ $ 64 ​ $ 420 ​ $ 484 2022 ​ — ​ 521 ​ 521 2023 ​ — ​ 246 ​ 246 2024 ​ ​ — ​ ​ 194 ​ ​ 194 2025 ​ ​ — ​ ​ 147 ​ ​ 147 Thereafter ​ — ​ 24 ​ 24 Total lease payments ​ 64 ​ 1,552 ​ 1,616 Less: imputed interest ​ (1) ​ (203) ​ (204) Present value of lease liabilities ​ ​ 63 ​ ​ 1,349 ​ ​ 1,412 Less: current portion of lease liabilities ​ 63 ​ 560 ​ 623 Noncurrent lease liabilities ​ $ — ​ $ 789 ​ $ 789 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Note: Future minimum lease payments exclude short-term leases as well as payments to landlords for variable common area maintenance, insurance and real estate taxes.

DEBT

DEBT	3 Months Ended
	Mar. 31, 2021
DEBT
DEBT	4. DEBT Paycheck Protection Program During March 2021, the Company received an unsecured loan under the United States Small Business Administration Paycheck Protection Program (“PPP”) in the amount of $1.7 million. Assure executed a PPP promissory note, which matures on February 25, 2026. The PPP Loan carries an interest rate of 1.0% per annum, with principal and interest payments due on the first day of each month, with payments commencing on the earlier of: (i) the day the amount of loan forgiveness granted to Assure is remitted by the Small Business Administration to the Bank of Oklahoma; or (ii) 10 months after the end of the 24 week period following the grant of the Loan. All or a portion of the Loan may be forgiven if the Company maintains its employment and compensation within certain parameters during the 24 week period following the loan origination date and the proceeds of the Loan are spent on payroll costs, rent or lease agreements dated before February 15, 2020 and utility payments arising under service agreements dated before February 15, 2020. ​ The Company’s debt obligations are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2021 2020 Bank line of credit ​ $ 1,978 ​ $ 1,978 Bank promissory note ​ 2,122 ​ 2,122 Payroll protection program loan ​ 1,665 ​ — ​ ​ 5,765 ​ 4,100 Face value of convertible debenture ​ 3,450 ​ 3,450 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 419 ​ ​ 324 ​ ​ 2,346 ​ 2,251 Total debt ​ 8,111 ​ 6,351 Less: current portion of debt ​ (4,100) ​ (4,100) Long-term debt ​ $ 4,011 ​ $ 2,251 ​ As of March 31, 2021, future minimum principal payments are summarized as follows (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Bank & PPP Convertible ​ ​ Indebtedness Debt Remainder 2021 ​ $ 4,100 ​ $ — 2022 ​ — ​ — 2023 ​ — ​ 965 2024 ​ — ​ 2,485 2025 ​ — ​ — 2026 ​ ​ 1,665 ​ ​ — Total ​ ​ 5,765 ​ ​ 3,450 Less: fair value ascribed to conversion feature and warrants ​ — ​ (1,523) Plus: accretion and implied interest ​ — ​ 419 ​ ​ $ 5,765 ​ $ 2,346 ​

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended
	Mar. 31, 2021
SHARE CAPITAL
SHARE CAPITAL	5. SHARE CAPITAL Common shares Common shares: 900,000,000 authorized; $0.001 par value. As of March 31, 2021 and December 31, 2020, there were 56,598,777 and 56,378,939 common shares issued outstanding Stock options On December 10, 2020, our shareholders approved amendments to the Company’s stock option plan, which amended the plan previously approved on November 20, 2019 (the “Amended Stock Option Plan”). As of March 31, 2021, an aggregate of 5,659,878 shares of common stock (10% of the issued and outstanding shares of common stock) were available for issuance under the Amended Stock Option Plan. Of this amount, stock options in respect of 4,983,000 common shares have been issued. ​ Options under the Plan are granted from time to time at the discretion of the Board of Directors, with vesting periods and other terms as determined by the Board of Directors. A summary of the stock option activity is presented below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2020 3,743,000 ​ $ 1.05 ​ 4.00 ​ ​ ​ Options granted 1,590,000 ​ $ 1.06 ​ ​ ​ ​ ​ Options exercised — ​ $ — ​ ​ ​ ​ ​ Options canceled / expired (350,000) ​ $ 1.20 ​ ​ ​ ​ ​ Balance at March 31, 2021 4,983,000 ​ $ 1.03 4.10 $ 2,922 Vested and exercisable at March 31, 2021 2,638,467 ​ $ 0.94 3.85 $ 773 ​ The following table summarizes information about stock options outstanding and exercisable under the Company’s Stock Option Plan at March 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 1,000,000 4.41 ​ $ 0.05 1,000,000 ​ $ 0.05 60,000 1.57 ​ $ 2.80 60,000 ​ $ 2.80 75,000 6.80 ​ $ 1.80 75,000 ​ $ 1.80 425,000 2.50 ​ $ 1.80 311,667 ​ $ 1.80 734,000 2.80 ​ $ 1.56 538,267 ​ $ 1.56 434,000 3.52 ​ $ 1.28 202,533 ​ $ 1.28 200,000 ​ 4.41 ​ $ 0.90 ​ 40,000 ​ $ 0.90 465,000 4.70 ​ $ 0.97 93,000 ​ $ 0.97 1,590,000 ​ 4.84 ​ $ 1.06 ​ 318,000 ​ $ 1.06 4,983,000 4.10 ​ $ 1.03 2,638,467 ​ $ 0.94 ​ The Company uses the Black-Scholes option pricing model to determine the estimated fair value of options. The fair value of each option grant is determined on the date of grant and the expense is recorded on a straight-line basis and is included as a component of general and administrative expense in the consolidated statements of operations. The assumptions used in the model include expected life, volatility, risk-free interest rate, dividend yield and forfeiture rate. The Company’s determination of these assumptions are outlined below. Expected life — Volatility — Risk-free interest rate — Dividend yield — Forfeiture rate — There were no stock option grants during the three months ended March 31, 2020.The following assumptions were used to value the awards granted during the three months ended March 31, 2021: ​ ​ ​ ​ ​ Expected life (in years) 5.0 Risk-free interest rate 0.4 % Dividend yield — % Expected volatility 91 % ​ Stock-based compensation expense recognized in our consolidated financial statements for the three months ended March 31, 2021 and 2020 was $279 thousand and $205 thousand, respectively. As of March 31, 2021, there was approximately $1.2 million of total unrecognized compensation cost related to 2,344,533 unvested stock options that is expected to be recognized over a weighted-average remaining vesting period of 2.6 years. ​ Derivative Liability ​ Stock options granted to consultants that have an exercise price this is stated in a different currency than the Company’s functional currency are treated as a liability and are revalued at the end of each reporting period for the term of the vesting period. Any change in the fair value of the stock option subsequent to the initial recognition is recorded as a component of other income, net in the consolidated statements of operations. ​ ​ Changes in the Company’s stock option liability for the three months ended March 31, 2021 was as follows (stated in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 16 Loss on revaluation ​ (3) Balance at March 31, 2021 ​ $ 19 ​ There were no stock options granted during the three months ended March 31, 2021. The assumptions used for the Black-Scholes Option Pricing Model to revalue the stock options granted to consultants as of March 31, 2021 were as follows: ​ ​ ​ ​ ​ Expected life (in years) 5.0 Risk-free interest rate 0.4 % Dividend yield — % Expected volatility 91 % ​ Warrants As of March 31, 2021 and December 31, 2020, there were 18,325,028 warrants outstanding.

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Mar. 31, 2021
LOSS PER SHARE
LOSS PER SHARE	6. LOSS PER SHARE The following table sets forth the computation of basic and fully diluted loss per common share for the three months ended March 31, 2021 and 2020 (stated in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2021 2020 Net loss ​ $ (1,231) ​ $ (414) Basic weighted average common shares outstanding ​ 56,537,711 ​ 34,795,313 Basic loss per common share ​ $ (0.02) ​ $ (0.01) Net loss ​ $ (1,231) ​ $ (414) Dilutive weighted average common shares outstanding ​ 56,537,711 ​ 34,795,313 Diluted loss per common share ​ $ (0.02) ​ $ (0.01) ​ Basic net loss per share is computed using the weighted average number of common shares outstanding during the period. Diluted net loss per share is computed using the treasury stock method to calculate the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential dilutive common shares include incremental common shares issuable upon the exercise of stock options, less shares from assumed proceeds. The assumed proceeds calculation includes actual proceeds to be received from the employee upon exercise and the average unrecognized stock compensation cost during the period. Stock options to purchase 2,638,467 common shares and warrants to purchase 18,325,028 common shares were outstanding at March 31, 2021 that were not included in the computation of diluted weighted average common shares outstanding because their effect would have been anti-dilutive.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2021
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Indemnifications The Company is a party to a variety of agreements in the ordinary course of business under which it may be obligated to indemnify third parties with respect to certain matters. These obligations include, but are not limited to, contracts entered into with physicians where the Company agrees, under certain circumstances, to indemnify a third party, against losses arising from matters including but not limited to medical malpractice and other liability. The impact of any such future claims, if made, on future financial results is not subject to reasonable estimation because considerable uncertainty exists as to final outcome of these potential claims. As permitted under Nevada law, the Company has agreements whereby it indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company’s request in such capacity. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company believes, given the absence of any such payments in the Company’s history, and the estimated low probability of such payments in the future, that the estimated fair value of these indemnification agreements is immaterial. In addition, the Company has directors’ and officers’ liability insurance coverage that is intended to reduce its financial exposure and may enable the Company to recover any payments, should they occur. Performance share compensation As part of a reverse takeover transaction (“RTO”) during 2016, the Company entered into a one-time stock grant agreement with two executives (Messrs. Preston Parsons and Matthew Willer (former Chief Financial Officer) which defines a bonus share threshold as follows: should the Company meet or exceed a 2017 fiscal year EBITDA threshold of Cdn$7,500, the Company would issue 6,000,000 common shares of the surviving issuer at the trailing 30-day average closing price. The performance share grant was structured as part of the RTO transaction to provide additional equity to management conditioned upon performance achievements. As the Company achieved the EBITDA threshold for the year ended December 31, 2017, the Company has recorded a liability of approximately $16 million for the value of the shares to be issued while the agreements are modified and the cash collected threshold is achieved, which the Company deems probable. During the year ended December 31, 2020, the Company settled 5,000,000 performance shares resulting from the issuance of 5,000,000 common shares. During the first quarter of 2021, the Company settled an additional 219,838 performance shares. As of March 31, 2021, 780,162 performance shares have not been settled. ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	8. SUBSEQUENT EVENTS Acquisition ​ On April 30, 2021, the Company completed its acquisition of Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas, for an aggregate purchase price of $3.5 million. The purchase price to be paid is $1.225 million in cash, payable in installments, and $2.3 million in Assure common stock, payable $1.625 million at closing and $650 thousand into escrow, subject to escrow release. The common stock is subject to 12-month lockup and applicable securities laws and regulations. ​ Board Appointment ​ On April 15, 2021, the Company appointed a new member to its Board of Directors. In connection with the appointment, the Company granted 150,000 stock options exercisable to acquire common stock at $1.12 per share for a period of five years. ​ Nasdaq listing On May 12, 2021, we filed an application to be listed on the Nasdaq. ​ ​

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2021
LEASES
Schedule of right of use assets	The consolidated balance sheets include the following amounts for right of use (“ROU”) assets as of March 31, 2021 and December 31, 2020 (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2021 2020 Operating $ 67 $ 124 Finance ​ 764 ​ 608 Total $ 831 $ 732
Schedule of components of lease cost	The following are the components of lease cost for operating and finance leases (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2021 2020 Lease cost: ​ ​ ​ ​ ​ ​ Operating leases ​ $ 64 ​ $ 44 Finance leases: ​ ​ ​ ​ ​ ​ Amortization of ROU assets ​ ​ 117 ​ ​ 111 Interest on lease liabilities ​ ​ 17 ​ ​ 18 Total finance lease cost ​ ​ 134 ​ ​ 129 Total lease cost ​ $ 198 ​ $ 173 ​ ​ The following are the weighted average lease terms and discount rates for operating and finance leases: ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2021 ​ Weighted average remaining lease term: ​ ​ ​ Operating leases 0.3 years Finance leases 3.5 years Weighted average discount rate: ​ ​ ​ Operating leases 6.9 % Finance leases 8.0 %
Schedule of future minimum lease payments and related lease liabilities of operating leases	Future minimum lease payments and related lease liabilities as of March 31, 2021 were as follows (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder 2021 ​ $ 64 ​ $ 420 ​ $ 484 2022 ​ — ​ 521 ​ 521 2023 ​ — ​ 246 ​ 246 2024 ​ ​ — ​ ​ 194 ​ ​ 194 2025 ​ ​ — ​ ​ 147 ​ ​ 147 Thereafter ​ — ​ 24 ​ 24 Total lease payments ​ 64 ​ 1,552 ​ 1,616 Less: imputed interest ​ (1) ​ (203) ​ (204) Present value of lease liabilities ​ ​ 63 ​ ​ 1,349 ​ ​ 1,412 Less: current portion of lease liabilities ​ 63 ​ 560 ​ 623 Noncurrent lease liabilities ​ $ — ​ $ 789 ​ $ 789
Schedule of future minimum lease payments and related lease liabilities of financing leases	Future minimum lease payments and related lease liabilities as of March 31, 2021 were as follows (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ Operating ​ Finance ​ Lease ​ ​ Leases ​ Leases ​ Liabilities Remainder 2021 ​ $ 64 ​ $ 420 ​ $ 484 2022 ​ — ​ 521 ​ 521 2023 ​ — ​ 246 ​ 246 2024 ​ ​ — ​ ​ 194 ​ ​ 194 2025 ​ ​ — ​ ​ 147 ​ ​ 147 Thereafter ​ — ​ 24 ​ 24 Total lease payments ​ 64 ​ 1,552 ​ 1,616 Less: imputed interest ​ (1) ​ (203) ​ (204) Present value of lease liabilities ​ ​ 63 ​ ​ 1,349 ​ ​ 1,412 Less: current portion of lease liabilities ​ 63 ​ 560 ​ 623 Noncurrent lease liabilities ​ $ — ​ $ 789 ​ $ 789

DEBT (Tables)

DEBT (Tables)	3 Months Ended
	Mar. 31, 2021
DEBT
Summary of debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2021 2020 Bank line of credit ​ $ 1,978 ​ $ 1,978 Bank promissory note ​ 2,122 ​ 2,122 Payroll protection program loan ​ 1,665 ​ — ​ ​ 5,765 ​ 4,100 Face value of convertible debenture ​ 3,450 ​ 3,450 Less: fair value ascribed to conversion feature and warrants ​ (1,523) ​ (1,523) Plus: accretion of implied interest ​ 419 ​ ​ 324 ​ ​ 2,346 ​ 2,251 Total debt ​ 8,111 ​ 6,351 Less: current portion of debt ​ (4,100) ​ (4,100) Long-term debt ​ $ 4,011 ​ $ 2,251
Schedule of future minimum principal payments	As of March 31, 2021, future minimum principal payments are summarized as follows (stated in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ Bank & PPP Convertible ​ ​ Indebtedness Debt Remainder 2021 ​ $ 4,100 ​ $ — 2022 ​ — ​ — 2023 ​ — ​ 965 2024 ​ — ​ 2,485 2025 ​ — ​ — 2026 ​ ​ 1,665 ​ ​ — Total ​ ​ 5,765 ​ ​ 3,450 Less: fair value ascribed to conversion feature and warrants ​ — ​ (1,523) Plus: accretion and implied interest ​ — ​ 419 ​ ​ $ 5,765 ​ $ 2,346

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of stock options activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ ​ Weighted Weighted ​ ​ ​ ​ ​ ​ Average ​ Average ​ ​ ​ ​ ​ Number of ​ Exercise ​ Remaining ​ Aggregate ​ ​ Shares Subject ​ Price Per ​ Contractual ​ Intrinsic Value ​ ​ to Options ​ Share ​ Life (in years) ​ (in thousands) Balance at December 31, 2020 3,743,000 ​ $ 1.05 ​ 4.00 ​ ​ ​ Options granted 1,590,000 ​ $ 1.06 ​ ​ ​ ​ ​ Options exercised — ​ $ — ​ ​ ​ ​ ​ Options canceled / expired (350,000) ​ $ 1.20 ​ ​ ​ ​ ​ Balance at March 31, 2021 4,983,000 ​ $ 1.03 4.10 $ 2,922 Vested and exercisable at March 31, 2021 2,638,467 ​ $ 0.94 3.85 $ 773
Schedule of stock options outstanding and exercisable	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options Outstanding ​ Options Exercisable ​ Weighted ​ ​ ​ ​ ​ Average ​ Weighted ​ ​ ​ Weighted ​ ​ Remaining ​ Average ​ ​ ​ Average Number of ​ Contractual ​ Exercise Price ​ Number ​ Exercise Price Outstanding ​ Life (in years) ​ Per Share ​ Exercisable ​ Per Share 1,000,000 4.41 ​ $ 0.05 1,000,000 ​ $ 0.05 60,000 1.57 ​ $ 2.80 60,000 ​ $ 2.80 75,000 6.80 ​ $ 1.80 75,000 ​ $ 1.80 425,000 2.50 ​ $ 1.80 311,667 ​ $ 1.80 734,000 2.80 ​ $ 1.56 538,267 ​ $ 1.56 434,000 3.52 ​ $ 1.28 202,533 ​ $ 1.28 200,000 ​ 4.41 ​ $ 0.90 ​ 40,000 ​ $ 0.90 465,000 4.70 ​ $ 0.97 93,000 ​ $ 0.97 1,590,000 ​ 4.84 ​ $ 1.06 ​ 318,000 ​ $ 1.06 4,983,000 4.10 ​ $ 1.03 2,638,467 ​ $ 0.94
Schedule of assumptions were used to determine fair value of the awards	​ ​ ​ ​ ​ Expected life (in years) 5.0 Risk-free interest rate 0.4 % Dividend yield — % Expected volatility 91 %
Schedule of changes in stock option liability	Changes in the Company’s stock option liability for the three months ended March 31, 2021 was as follows (stated in thousands): ​ ​ ​ ​ ​ Balance at December 31, 2020 ​ $ 16 Loss on revaluation ​ (3) Balance at March 31, 2021 ​ $ 19
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of assumptions were used to determine fair value of the awards	​ ​ ​ ​ ​ Expected life (in years) 5.0 Risk-free interest rate 0.4 % Dividend yield — % Expected volatility 91 %

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2021
LOSS PER SHARE
Schedule of computation of basic and fully diluted loss per common share	The following table sets forth the computation of basic and fully diluted loss per common share for the three months ended March 31, 2021 and 2020 (stated in thousands, except per share amounts): ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2021 2020 Net loss ​ $ (1,231) ​ $ (414) Basic weighted average common shares outstanding ​ 56,537,711 ​ 34,795,313 Basic loss per common share ​ $ (0.02) ​ $ (0.01) Net loss ​ $ (1,231) ​ $ (414) Dilutive weighted average common shares outstanding ​ 56,537,711 ​ 34,795,313 Diluted loss per common share ​ $ (0.02) ​ $ (0.01)

NATURE OF OPERATIONS - (Narrati

NATURE OF OPERATIONS - (Narrative) (Details)	3 Months Ended
	Mar. 31, 2021subsidiarysegment
NATURE OF OPERATIONS
Number of indirect wholly-owned subsidiaries | subsidiary	2
Number of operating segments | segment	1

LEASES - (Details)

LEASES - (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)item	Dec. 31, 2020USD ($)
Lessee, Lease, Description [Line Items]
Number of operating lease sub leases | item	2
Operating lease right of use asset	$ 67	$ 124
Finance lease right of use asset	764	608
Total right of use asset	831	732
Accumulated amortization of finance lease assets	$ 1,400	$ 1,300
Minimum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	6.50%
Maximum
Lessee, Lease, Description [Line Items]
Rate of interest for finance lease	12.20%

LEASES - Components of lease co

LEASES - Components of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Lease cost:
Operating leases	$ 64	$ 44
Amortization of ROU assets	117	111
Interest on lease liabilities	17	18
Total finance lease cost	134	129
Total lease cost	$ 198	$ 173

LEASES - Lease terms and discou

LEASES - Lease terms and discount rates (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2021USD ($)
LEASES
Weighted average remaining lease term: Operating leases (in years)	3 months 18 days
Weighted average remaining lease term: Financing leases (in years)	3 years 6 months
Weighted average discount rate: Operating leases (as a percent)	6.90%
Weighted average discount rate: Financing leases (as a percent)	8.00%
ROU assets acquired in exchange for finance lease liabilities	$ 273

LEASES - Future minimum lease p

LEASES - Future minimum lease payments (Details) $ in Thousands	Mar. 31, 2021USD ($)
Operating Leases
Remainder 2021	$ 64
Total lease payments	64
Less: imputed interest	(1)
Present value of lease liabilities	63
Less: current portion of lease liabilities	63
Finance Leases
Remainder 2021	420
2022	521
2023	246
2024	194
2025	147
Thereafter	24
Total lease payments	1,552
Less: imputed interest	(203)
Present value of lease liabilities	1,349
Less: current portion of lease liabilities	560
Noncurrent lease liabilities	789
Total Lease Liabilities
Remainder 2021	484
2022	521
2023	246
2024	194
2025	147
Thereafter	24
Total lease payments	1,616
Less: imputed interest	(204)
Present value of lease liabilities	1,412
Less: current portion of lease liabilities	623
Noncurrent lease liabilities	$ 789

DEBT - Debt Obligations (Detail

DEBT - Debt Obligations (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt
Bank debt obligations	$ 5,765	$ 4,100
Less: fair value ascribed to conversion feature and warrants	(1,523)	(1,523)
Plus: accretion of implied interest	419	324
Total	2,346	2,251
Total debt	8,111	6,351
Less: Current portion	(4,100)	(4,100)
Long-term debt	4,011	2,251
Bank line of credit
Debt
Bank debt obligations	1,978	1,978
Bank promissory note
Debt
Bank debt obligations	2,122	2,122
Payroll protection program loan
Debt
Bank debt obligations	1,665
Face amount	1,700
Convertible debenture
Debt
Face amount	$ 3,450	$ 3,450

DEBT - Future minimum principal

DEBT - Future minimum principal payments (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Total	$ 2,346	$ 2,251
Less: fair value ascribed to conversion feature and warrants	(1,523)	(1,523)
Plus: accretion of implied interest	419	324
Total debt	8,111	$ 6,351
Bank & PPP Indebtedness
Debt Instrument [Line Items]
Remainder 2021	4,100
2026	1,665
Total	5,765
Total debt	5,765
Convertible Debt
Debt Instrument [Line Items]
2023	965
2024	2,485
Total	3,450
Less: fair value ascribed to conversion feature and warrants	(1,523)
Plus: accretion of implied interest	419
Total debt	$ 2,346

SHARE CAPITAL - (Narrative) (De

SHARE CAPITAL - (Narrative) (Details) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
SHARE CAPITAL
Common stock, shares authorized	900,000,000	900,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares issued	56,598,777	56,378,939
Common stock, shares outstanding	56,598,777	56,378,939

SHARE CAPITAL - Stock Options (

SHARE CAPITAL - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options granted (in shares)	0	0
Stock options
Share Capital
Shares available for issuance	5,659,878
Maximum percentage	10.00%
Shares issued	4,983,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Options at beginning of period (in shares)	3,743,000
Options granted (in shares)	1,590,000
Options canceled / expired (in shares)	(350,000)
Options at end of period (in shares)	4,983,000		3,743,000
Options vested and exercisable as at end of the period	2,638,467
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]
Exercise Price at beginning of period (in dollars per share)	$ 1.05
Options granted (in dollars per share)	1.06
Options canceled / expired (in dollars per share)	1.20
Exercise Price at end of period (in dollars per share)	1.03		$ 1.05
Exercise Price vested and exercisable (in dollars per share)	$ 0.94
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average Remaining life (in years)	4 years 1 month 6 days		4 years
Weighted Average Remaining life vested and exercisable (in years)	3 years 10 months 6 days
Aggregate Intrinsic Value	$ 2,922
Aggregate Intrinsic Value vested and exercisable	$ 773

SHARE CAPITAL - Stock Options o

SHARE CAPITAL - Stock Options outstanding and exercisable (Details) - Stock options - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	4,983,000	3,743,000
Weighted Average Remaining life (in years)	4 years 1 month 6 days	4 years
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.03	$ 1.05
Number Exercisable (in shares)	2,638,467
Exercise Price exercisable (in dollars per share)	$ 0.94
Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	1,000,000
Weighted Average Remaining life (in years)	4 years 4 months 28 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 0.05
Number Exercisable (in shares)	1,000,000
Exercise Price exercisable (in dollars per share)	$ 0.05
Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	60,000
Weighted Average Remaining life (in years)	1 year 6 months 25 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 2.80
Number Exercisable (in shares)	60,000
Exercise Price exercisable (in dollars per share)	$ 2.80
Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	75,000
Weighted Average Remaining life (in years)	6 years 9 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.80
Number Exercisable (in shares)	75,000
Exercise Price exercisable (in dollars per share)	$ 1.80
Range Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	425,000
Weighted Average Remaining life (in years)	2 years 6 months
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.80
Number Exercisable (in shares)	311,667
Exercise Price exercisable (in dollars per share)	$ 1.80
Range Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	734,000
Weighted Average Remaining life (in years)	2 years 9 months 18 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.56
Number Exercisable (in shares)	538,267
Exercise Price exercisable (in dollars per share)	$ 1.56
Range Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	434,000
Weighted Average Remaining life (in years)	3 years 6 months 7 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.28
Number Exercisable (in shares)	202,533
Exercise Price exercisable (in dollars per share)	$ 1.28
Range Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	200,000
Weighted Average Remaining life (in years)	4 years 4 months 28 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 0.90
Number Exercisable (in shares)	40,000
Exercise Price exercisable (in dollars per share)	$ 0.90
Range Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	465,000
Weighted Average Remaining life (in years)	4 years 8 months 12 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 0.97
Number Exercisable (in shares)	93,000
Exercise Price exercisable (in dollars per share)	$ 0.97
Range Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding (in shares)	1,590,000
Weighted Average Remaining life (in years)	4 years 10 months 2 days
Weighted average exercise price of options outstanding (in dollars per share)	$ 1.06
Number Exercisable (in shares)	318,000
Exercise Price exercisable (in dollars per share)	$ 1.06

SHARE CAPITAL - Assumptions use

SHARE CAPITAL - Assumptions used (Details)	3 Months Ended
	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years
Risk-free interest rate	0.40%
Expected volatility	91.00%
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	5 years
Risk-free interest rate	0.40%
Expected volatility	91.00%

SHARE CAPITAL - Stock-based com

SHARE CAPITAL - Stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
SHARE CAPITAL
Stock-based compensation expense recognized	$ 279	$ 205
Unrecognized compensation cost	$ 1,200
Unvested stock options (in shares)	2,344,533
Weighted-average remaining vesting period	2 years 7 months 6 days

SHARE CAPITAL - Changes in Stoc

SHARE CAPITAL - Changes in Stock Option Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Fair value of the stock option derivative liability
Balance at Beginning of period	$ 16
Loss on revaluation	(3)
Balance at End of period	$ 19
Stock options granted	0	0
Warrants outstanding	18,325,028		18,325,028

LOSS PER SHARE (Details)

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net loss	$ (1,231)	$ (414)
Basic weighted average common share outstanding	56,537,711	34,795,313
Basic loss per common share	$ (0.02)	$ (0.01)
Dilutive weighted average common shares outstanding	56,537,711	34,795,313
Diluted loss per common share	$ (0.02)	$ (0.01)
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Options exercised (in shares)	2,638,467
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number common shares to purchase of warrants	18,325,028

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - Performance Shares $ in Thousands, $ in Millions	Nov. 08, 2016CAD ($)itemshares	Mar. 31, 2021shares	Dec. 31, 2020shares	Dec. 31, 2017USD ($)
Commitments and Contingencies
Number of executives | item	2
EBITDA threshold | $	$ 7,500
Shares issued	6,000,000		5,000,000
Trailing days for average closing price	30 days
Liability recorded for value of shares | $				$ 16
Number of performances shares settled		219,838	5,000,000
Number of performance shares not yet settled		780,162

SUBSEQUENT EVENTS (Narrative) (

SUBSEQUENT EVENTS (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	Apr. 15, 2021	Apr. 30, 2021	Mar. 31, 2021	Mar. 31, 2020
Subsequent Events
Stock options granted			0	0
Subsequent Events
Subsequent Events
Stock options granted	150,000
Share price	$ 1.12
Stock option exercisable term	5 years
Subsequent Events | Sentry Neuromonitoring, LLC
Subsequent Events
Purchase price		$ 3,500
Consideration paid		1,225
Value of common stock issuable		2,300
Consideration payable at closing		1,625
Escrow Deposit		$ 650
Common stock lock up period		12 months